Toujeo is a long-acting insulin formulation containing insulin glargine at a higher concentration of 300 units per millilitre. It is designed to provide consistent, 24-hour blood sugar control in people with diabetes. Toujeo is primarily used in the management of both type 1 and type 2 diabetes in adults, and sometimes in children, to help maintain stable glucose levels throughout the day and night.

Mechanism of Action
Toujeo contains insulin glargine, a modified form of human insulin. After injection under the skin, it forms micro-precipitates that slowly release insulin into the bloodstream. This allows for a steady and prolonged insulin effect, mimicking the natural background insulin secretion of the body.

The main function of insulin is to help glucose enter the cells from the blood, where it is used for energy. By lowering glucose levels in this controlled way, Toujeo helps reduce the risk of high blood sugar (hyperglycaemia) without causing large fluctuations.

Toujeo differs from other insulins by offering a flatter and longer activity profile with less risk of nighttime hypoglycaemia compared to insulin glargine 100 units/mL.

Uses
Toujeo is prescribed for:

• Type 1 diabetes: As a part of a basal-bolus insulin regimen alongside rapid-acting insulin

• Type 2 diabetes: When blood sugar cannot be adequately managed with oral medicines or other injectable treatments alone

• It helps maintain fasting blood sugar levels and provides a stable foundation for overall glycaemic control

  Adverse Effects

  Common side effects:

  • Low blood sugar (hypoglycaemia), especially when meals are delayed or skipped

  • Weight gain due to increased glucose uptake

  • Injection site reactions such as redness or swelling

  • Mild swelling of hands or feet (fluid retention)